CA3110839A1 - Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents - Google Patents

Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents Download PDF

Info

Publication number
CA3110839A1
CA3110839A1 CA3110839A CA3110839A CA3110839A1 CA 3110839 A1 CA3110839 A1 CA 3110839A1 CA 3110839 A CA3110839 A CA 3110839A CA 3110839 A CA3110839 A CA 3110839A CA 3110839 A1 CA3110839 A1 CA 3110839A1
Authority
CA
Canada
Prior art keywords
compound
ome
substituted
unsubstituted
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3110839A
Other languages
English (en)
French (fr)
Inventor
Bert W. O'malley
David Michael LONARD
Yongcheng Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of CA3110839A1 publication Critical patent/CA3110839A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA3110839A 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents Pending CA3110839A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862724281P 2018-08-29 2018-08-29
US62/724,281 2018-08-29
US201962825358P 2019-03-28 2019-03-28
US62/825,358 2019-03-28
PCT/US2019/048703 WO2020047186A1 (en) 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Publications (1)

Publication Number Publication Date
CA3110839A1 true CA3110839A1 (en) 2020-03-05

Family

ID=67982135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3110839A Pending CA3110839A1 (en) 2018-08-29 2019-08-29 Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

Country Status (7)

Country Link
US (4) US10875841B2 (https=)
EP (1) EP3843843A1 (https=)
JP (3) JP7495138B2 (https=)
CN (2) CN120136844A (https=)
AU (2) AU2019333119B2 (https=)
CA (1) CA3110839A1 (https=)
WO (1) WO2020047186A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120136844A (zh) * 2018-08-29 2025-06-13 贝勒医学院 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法
KR20230093329A (ko) 2020-10-28 2023-06-27 베이롤 칼리지 오브 메드신 암의 치료를 위한 면역조절 치료제로서 면역 세포에서 src-3의 표적화
WO2025240566A1 (en) * 2024-05-17 2025-11-20 Baylor College Of Medicine Small molecule steroid receptor coactivator stimulators for use in repairing tissue

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112205A0 (en) 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
CA2393440A1 (en) 1999-12-03 2001-06-07 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20070010488A1 (en) 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
CN102381951B (zh) 2007-01-22 2013-09-04 温州医学院生物与天然药物开发中心有限公司 含环己酮的姜黄素单羰基结构类似物及其用途
EP2170311A4 (en) 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
US20100197584A1 (en) 2007-07-27 2010-08-05 Research Foundations of the City University of- New York Use of curcumin to block brain tumor formation in mice
WO2009144220A1 (en) 2008-05-29 2009-12-03 Universite Libre De Bruxelles Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy
US8420118B2 (en) * 2009-09-10 2013-04-16 The Board Of Regents Of The University Of Oklahoma Anionic lipids and lipid nano-structures and methods of producing and using same
WO2011029359A1 (zh) 2009-09-12 2011-03-17 温州医学院 含11β-羟基甾体脱氢酶1双重调节剂的药物及其应用
JP2011074024A (ja) * 2009-09-30 2011-04-14 Shiseido Co Ltd ヘパラナーゼ活性阻害剤並びにそれを含有するしわ改善剤及び医薬組成物
WO2011127333A2 (en) 2010-04-09 2011-10-13 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2012021692A1 (en) 2010-08-11 2012-02-16 Rutgers, The State University Of New Jersey Curcumin analogs and methods of use thereof
CN102153508B (zh) * 2010-10-08 2013-01-09 福建医科大学 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用
CN103012088B (zh) 2012-11-28 2017-01-11 江苏药兴医药股份有限公司 α-(3,5-二甲氧基苯亚甲基)-α'-烃基亚甲基环酮及其制备方法
ITMI20130075A1 (it) 2013-01-21 2014-07-22 Altergon Sa Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale
CN103181922A (zh) * 2013-04-02 2013-07-03 温州医学院 一类含哌啶酮的单羰基姜黄素类化合物在制备抗炎药物中的应用
WO2016109470A1 (en) 2014-12-30 2016-07-07 Baylor College Of Medicine Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
WO2017062751A1 (en) * 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
CN106083704B (zh) * 2016-06-06 2018-07-27 福建医科大学 3,5-(E)-二芳亚甲基-N-环丙基哌啶-4-酮类化合物作为Hsp90抑制剂的应用
EP3713916A1 (en) * 2017-11-20 2020-09-30 Kiakos, Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
CN120136844A (zh) * 2018-08-29 2025-06-13 贝勒医学院 类固醇受体共激活剂-3的小分子刺激剂以及它们用作心脏保护剂和/或血管再生剂的方法

Also Published As

Publication number Publication date
JP2024102352A (ja) 2024-07-30
EP3843843A1 (en) 2021-07-07
AU2019333119B2 (en) 2025-06-05
JP2021534221A (ja) 2021-12-09
CN120136844A (zh) 2025-06-13
US20230357200A1 (en) 2023-11-09
CN112955217B (zh) 2025-04-08
AU2025226726A1 (en) 2025-09-25
CN112955217A (zh) 2021-06-11
US20250282755A1 (en) 2025-09-11
AU2019333119A1 (en) 2021-03-18
US12338229B2 (en) 2025-06-24
JP2025183370A (ja) 2025-12-16
WO2020047186A1 (en) 2020-03-05
JP7495138B2 (ja) 2024-06-04
US10875841B2 (en) 2020-12-29
JP7777263B2 (ja) 2025-11-28
US11708350B2 (en) 2023-07-25
US20200071300A1 (en) 2020-03-05
US20210115017A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
US12338229B2 (en) Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
Liu et al. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma
García-Martín et al. EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice
CN110325188A (zh) 小分子蛋白质精氨酸甲基转移酶5(prmt5)抑制剂和治疗方法
Wang et al. Gomisin D alleviates liver fibrosis through targeting PDGFRβ in hepatic stellate cells
EP3104847B1 (en) Novel use of sigma-1 receptor agonist compounds
Boratyńska et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies
EP3600301B1 (en) Kdm4 inhibitors
Wang et al. A novel and low-toxic peptide DR3penA alleviates pulmonary fibrosis by regulating the MAPK/miR-23b-5p/AQP5 signaling axis
Shen et al. Lack of PPARβ/δ‐inactivated SGK‐1 is implicated in liver carcinogenesis
Erdmann et al. Pioglitazone and mechanisms of CV protection
Shi et al. Silencing FHL2 inhibits bleomycin-induced pulmonary fibrosis through the TGF-β1/Smad signaling pathway
CN109069467B (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
Vieira Jr et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease
Chen et al. Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma
Borrello et al. Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors
EP2924037A1 (en) Quinazoline derivate and use thereof as apoptosis inhibitor
Sanders et al. The inhibitory effect of rapamycin on the oval cell response and development of preneoplastic foci in the rat
Qin et al. Small molecule-driven LKB1 deacetylation is responsible for the inhibition of hepatic lipid response in NAFLD
CN119424402A (zh) L-犬尿氨酸在治疗免疫检查点抑制剂相关心肌炎中的应用
CN111840557A (zh) 磷酸二酯酶4抑制剂的用途
TW201423102A (zh) 抗癌藥物之篩選方法及治療癌症之方法
JP7759032B2 (ja) 脳血管攣縮抑制剤
Wang et al. Tripterygium Wilfordii Reduces the Inflammatory Response in Transplant Vasculopathy
US20220226339A1 (en) Inhibitation of acid lipase for cancer therapy

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240805

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240805

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240829

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250306

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250310

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250310

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250310

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250508

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250926

R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED

Effective date: 20251020